**Table S2:** Factors associated with Overall survival (OS2) among enrolled patients (excluded those who lost to follow-up, choose those variables with *p*<0.1 into multivariate analysis) (n=97)

|  |  |  |  |
| --- | --- | --- | --- |
| Factors | OS2 | | |
| Univariate | | Multivariate |
| HR | *p*-value | HR (95%CI) |
| Age group (≥ 50 years vs.<50 years ) | 1.022 | 0.946 |  |
| ER (Positive vs. Negative) | 0.716 | 0.304 |  |
| PR (Positive vs. Negative) | 0.689 | 0.263 |  |
| HER2 (Negative vs. Positive) | 1.068 | 0.848 |  |
| TNBC (Yes vs. No) | 1.825 | 0.123 |  |
| Number of metastatic sites (≥2 sites vs. <2) | 1.804 | 0.140 |  |
| Type of metastatic sites |  |  |  |
| 2\* vs. 1\* | 1.232 | 0.554 |  |
| 3\* vs. 1\* | 0.760 | 0.672 |  |
| Eribulin line of therapy (Late-line vs. Early-line) | 4.543 | **0.012** | 4.543  (1.394- 14.802) |
| HR=hazard ratio; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2, TNBC=triple negative breast cancer, 1\*=Non-visceral metastasis and/or recurrent disease, 2\*=Both visceral and non-visceral metastasis, 3\*=Visceral metastasis | | | |